Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment). The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI’s November 24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant. Sci

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year end These agreements ensure BioAtla can maintain operational momentum while completing that process Nov. 21, 2025 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developme

- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - Nov. 20, 2025 -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced the first closing of its previously announced private placement (“PIPE”). Additionally, the Company announ

Nov. 19, 2025 -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the receipt of a Notice of Award of a grant from the NIH/NINDS and entry into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation. On September 23, 2025, RespireRx received a Notice of Award from t

The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinactant and AEROSURF® (a drug and device combination) The franchise is intended to treat premature infants with respiratory distress syndrome (RDS) Windtree will communicate more information about milestone payments it may receive from its licensing part

Nov. 17, 2025 -- Angiex Inc., a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, today announced the completion of financings totaling $31 million, with participation from new and existing investors. The proceeds are being used to advance AGX101, a first-in-class TM4SF1-directed ND-ADC, through the dose-escalation portion of the Phase 1 clinical trial, which is designed to assess safety, tolerability and preliminary clinical activity. “Angiex is ver

Nov. 14, 2025 -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the first tranche (the “First Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025. Gross proceeds from the First Tranche totaled CAD $177,000 from the sale of 2,528,752 units (the “Units”) at an issue price of CAD $0.07 per Unit. Certain insiders of the Company participated

$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025 – T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising a further $32 million. Followi

New funding brings total capital raised to $135 million Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins Nov. 13, 2025 -- Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to

Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Annamycin targets key factors in pancreatic cancer Nov. 12, 2025 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered i